Aa
A
A
A
Close
Hepatitis C Community
13.4k Members
1815939 tn?1377995399

Liver Fibrosis Develops Early, Progresses Quickly After HCV Seroconversion

From Medscape:  

Liver Fibrosis Develops Early, Progresses Quickly After Hepatitis C Virus Seroconversion
By Will Boggs MD, December 14, 2014

Liver fibrosis develops early after hepatitis C virus (HCV) seroconversion and progresses quickly to cirrhosis in many patients, according to new findings.

"Within 10 years of HCV infection, about 18% have developed cirrhosis, and this is 3 times higher than controls," Dr. Adeel A. Butt from University of Pittsburgh School of Medicine in Pennsylvania told Reuters Health by email. "Most of this occurs within the first 5 years after infection."

Dr. Butt and colleagues used the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to identify 1,840 patients who seroconverted to HCV antibody and then to determine their rate of liver fibrosis progression, compared with 1,840 matched controls who remained HCV antibody-negative.

They plotted the FIB-4 score, which provides an estimation of the degree of liver fibrosis based on routinely obtained blood tests, over time. A FIB-4 score greater than 3.5 indicates cirrhosis.

FIB-4 score progression started early after seroconversion, was most pronounced within the first five years, and continued over a period of 11 years. Progression was consistently higher among HCV-positive patients than among HCV-negative patients, the researchers report in JAMA Internal Medicine, online December 8.

In the HCV-positive group, 18.4% of patients went on to develop cirrhosis, compared with only 6.1% in the HCV-negative group, and the HCV-positive patients had a significantly shorter time to development of liver cirrhosis.

By five years, more than 15% of HCV-positive patients had a diagnosis of cirrhosis, compared with less than 5% of HCV-negative controls.

Only 3.1% of patients in the HCV-positive group developed hepatic decompensation (compared with 1.4% of HCV-negative patients), but their time to first hepatic decompensation was significantly shorter than it was for HCV-negative patients. More than half of the hepatic decompensation events occurred within the first two years of diagnosis of cirrhosis.

Factors associated with a higher risk of cirrhosis among HCV-positive patients included increasing age, white race, hypertension, history of alcohol abuse or dependence, and anemia. Diabetes, hypertension, and anemia were associated with a higher risk of developing hepatic decompensation.

"Future studies should look at a risk prediction model to determine which characteristics most accurately predict future cirrhosis in a given individual," Dr. Butt said. "Contrary to popular thought, a significant proportion of hepatic decompensation occurs without prior diagnosis of cirrhosis. Hence careful follow-up and evaluation for hepatic decompensation should be carried out in all HCV-infected persons regardless of duration of infection and prior diagnosis of cirrhosis."

"If newer treatments demonstrate slowing or reversal of fibrosis progression and delaying development of cirrhosis, our data would suggest treating early in the course of infection," the authors conclude. "On the other hand, if the cirrhosis has already set in, treatment may be helpful in preventing hepatic decompensation in only a small number of those with cirrhosis, since the number who go on to develop this complication is small."

Dr. Marc G. Ghany from the National Institute of Diabetes and Digestive and Kidney Diseases in Bethesda, Maryland, addressed the ongoing debate of whom to treat for chronic HCV in a related editorial.

"All patients with chronic HCV infection should be considered candidates for therapy, and mild liver disease is not a reason to deny a patient therapy who otherwise qualifies for treatment," he told Reuters Health by email.

But treatment is expensive, with costs ranging from $66,000 for 12 weeks of treatment with simeprevir to $84,000 for 12 weeks of treatment with sofosbuvir.

"The hope is that with the approval of other regimens, competition will drive down costs," Dr. Ghany said. "It remains to be seen how much cheaper the drugs will become, but it is unlikely in the near future that costs will decrease to the point where we will be able to treat everyone who is infected with hepatitis C virus."

"We still have to identify the large number of people who are unaware of their diagnosis and get them into care, including counseling on measures to prevent transmission, disease progression, and treatment," he concluded.

"This kind of study should remind physicians about the importance of non-viral, modifiable factors of accelerated liver fibrosis progression," Dr. Francesco Negro from Geneva University Hospital in Switzerland, who has published extensively on HCV infection, told Reuters Health. "One may think that treating HCV with antivirals may be the end of the story, thus forgetting about the formidable impact of alcohol drinking, cannabis smoking, and the metabolic syndrome. The VA population is particularly vulnerable in this respect."

"That their progression seemed to slow down once the diagnosis of cirrhosis was made suggests (although other explanations may be possible) that these persons became aware of the severity of their liver disease and tried to adopt a healthier lifestyle," said Dr. Negro, who was not involved in the research. "If this is true, our job should be to avoid reaching the cirrhotic stage, a stage when the risk of developing liver cancer may be hard to eliminate completely."

"We still have a lot of things to learn regarding the pathophysiology of hepatitis C," he said.
39 Responses
Avatar universal
This is really a good article Pooh. Thanks for posting it. I hope people take the time and really read it. Just maybe some of the misinformation being posted here anymore will stop.

Being cirrhotic this really jumped out at me.

"On the other hand, if the cirrhosis has already set in, treatment may be helpful in preventing hepatic decompensation in only a small number of those with cirrhosis, since the number who go on to develop this complication is small."

Not only is he saying its still possible to go on to decompensation but not a damn word on reversing cirrhosis. Which I already knew.
Avatar universal
The article is not about reversing cirrhosis but rather it's about who should be treated. I think what he says in the quote here can-do is that those who actually develop cirrhosis are a small number so giving this group the highest priority for treatment is not the best approach since once you already have cirrhosis you may move into decompensation regardless of being cured of hcv. Better to spend the money on those who have a greater chance of a healthy survival.

Since the topic is not about reversal of cirrhosis I don't think you can imply that it is not possible from what is said here. I think the guidelines were developed for people on Medicaid since they probably are a very large number of those who need tx. The idea is to postpone tx until there is more competition in pricing and the healthy can wait while those with cirrhosis may not be able to wait. There is really no good reason why more people shouldn't be treated except that politics dictates warehousing. It's going to take a few more articles like this before those in control change their game. But then again, who is to say what this new year will bring.
Avatar universal
Excellent article and comments!
Avatar universal
Wow. I guess I am odd woman out here. I do not think this is a good article at all. Although the points that Sarah makes are excellent.

Starting with the statement that 18% of people develop cirrhosis in the first 10 years just goes against everything I have ever heard or read. In fact Dr. Ghany  was one of the NIH docs on our advisory panel for our HCV education program and he believes what the CDC says. And that is that 5-20% of people progress to cirrhosis in the first 20 years after diagnosis. So while fibrosis may occur rather quickly, I highly doubt that 18% of patients go on to cirrhosis in 10 years.Also, I do know very much about how to judge the validity of studies but I do know that retrospective studies (look back) are not considered the best way to get information.

Just my opinion, guys.
Avatar universal
Sheesh, I mean to say that I do NOT know how to judge validity of studies.
Avatar universal
(from the article)

"Dr. Butt and colleagues used the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to identify 1,840 patients who seroconverted to HCV antibody and then to determine their rate of liver fibrosis progression, compared with 1,840 matched controls who remained HCV antibody-negative."
=============================

We have no idea how they selected those to study. (either the veteran group HCV infected or so called control group)
WE DO know that they are veterans; a sub-group that probably does not represent the aggregate of HCV infected.


Your thread title does not make that clear and perhaps even hides that fact.

(from the article)===========
"They plotted the FIB-4 score, which provides an estimation of the degree of liver fibrosis based on routinely obtained blood tests, over time. A FIB-4 score greater than 3.5 indicates cirrhosis. "
===============================================
Blood tests are not reliable; were they confirmed with biopsy? I could not tell that they were.
I had 2 fibrotests (one fibrosure and another competitor)  and a third test; ratio algorithm which indicated cirrhosis,
and the biopsy showed.....

stage 2.

....so much for blood tests

Willy


Have an Answer?
Top Hepatitis Answerers
317787 tn?1473362051
DC
683231 tn?1467326617
Auburn, WA
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Answer a few simple questions about your Hep C treatment journey.

Those who qualify may receive up to $100 for their time.
Explore More In Our Hep C Learning Center
image description
Learn about this treatable virus.
image description
Getting tested for this viral infection.
image description
3 key steps to getting on treatment.
image description
4 steps to getting on therapy.
image description
What you need to know about Hep C drugs.
image description
How the drugs might affect you.
image description
These tips may up your chances of a cure.
Popular Resources
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Here’s how your baby’s growing in your body each week.
These common ADD/ADHD myths could already be hurting your child
This article will tell you more about strength training at home, giving you some options that require little to no equipment.
In You Can Prevent a Stroke, Dr. Joshua Yamamoto and Dr. Kristin Thomas help us understand what we can do to prevent a stroke.
Smoking substitute may not provide such a healthy swap, after all.